These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 35614551)

  • 1. Dynamics of Nigral Iron Accumulation in Parkinson's Disease: From Diagnosis to Late Stage.
    Du G; Wang E; Sica C; Chen H; De Jesus S; Lewis MM; Kong L; Connor J; Mailman RB; Huang X
    Mov Disord; 2022 Aug; 37(8):1654-1662. PubMed ID: 35614551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative Susceptibility Mapping in Parkinson's Disease.
    Langkammer C; Pirpamer L; Seiler S; Deistung A; Schweser F; Franthal S; Homayoon N; Katschnig-Winter P; Koegl-Wallner M; Pendl T; Stoegerer EM; Wenzel K; Fazekas F; Ropele S; Reichenbach JR; Schmidt R; Schwingenschuh P
    PLoS One; 2016; 11(9):e0162460. PubMed ID: 27598250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreased serum ceruloplasmin levels characteristically aggravate nigral iron deposition in Parkinson's disease.
    Jin L; Wang J; Zhao L; Jin H; Fei G; Zhang Y; Zeng M; Zhong C
    Brain; 2011 Jan; 134(Pt 1):50-8. PubMed ID: 21109502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Signal alterations of the basal ganglia in the differential diagnosis of Parkinson's disease: a retrospective case-controlled MRI data bank analysis.
    Jesse S; Kassubek J; Müller HP; Ludolph AC; Unrath A
    BMC Neurol; 2012 Dec; 12():163. PubMed ID: 23273141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative evaluation of brain iron accumulation in different stages of Parkinson's disease.
    Li KR; Avecillas-Chasin J; Nguyen TD; Gillen KM; Dimov A; Chang E; Skudin C; Kopell BH; Wang Y; Shtilbans A
    J Neuroimaging; 2022 Mar; 32(2):363-371. PubMed ID: 34904328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantifying iron deposition within the substantia nigra of Parkinson's disease by quantitative susceptibility mapping.
    An H; Zeng X; Niu T; Li G; Yang J; Zheng L; Zhou W; Liu H; Zhang M; Huang D; Li J
    J Neurol Sci; 2018 Mar; 386():46-52. PubMed ID: 29406966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined Application of Quantitative Susceptibility Mapping and Diffusion Kurtosis Imaging Techniques to Investigate the Effect of Iron Deposition on Microstructural Changes in the Brain in Parkinson's Disease.
    Yang L; Cheng Y; Sun Y; Xuan Y; Niu J; Guan J; Rong Y; Jia Y; Zhuang Z; Yan G; Wu R
    Front Aging Neurosci; 2022; 14():792778. PubMed ID: 35370619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Region-specific disturbed iron distribution in early idiopathic Parkinson's disease measured by quantitative susceptibility mapping.
    He N; Ling H; Ding B; Huang J; Zhang Y; Zhang Z; Liu C; Chen K; Yan F
    Hum Brain Mapp; 2015 Nov; 36(11):4407-20. PubMed ID: 26249218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Iron deposition in Parkinson's disease by quantitative susceptibility mapping.
    Chen Q; Chen Y; Zhang Y; Wang F; Yu H; Zhang C; Jiang Z; Luo W
    BMC Neurosci; 2019 May; 20(1):23. PubMed ID: 31117957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum cholesterol and nigrostriatal R2* values in Parkinson's disease.
    Du G; Lewis MM; Shaffer ML; Chen H; Yang QX; Mailman RB; Huang X
    PLoS One; 2012; 7(4):e35397. PubMed ID: 22530017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extra-basal ganglia iron content and non-motor symptoms in drug-naïve, early Parkinson's disease.
    Kim M; Yoo S; Kim D; Cho JW; Kim JS; Ahn JH; Mun JK; Choi I; Lee SK; Youn J
    Neurol Sci; 2021 Dec; 42(12):5297-5304. PubMed ID: 33860863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low plasma serotonin linked to higher nigral iron in Parkinson's disease.
    Jellen LC; Lewis MM; Du G; Wang X; Galvis MLE; Krzyzanowski S; Capan CD; Snyder AM; Connor JR; Kong L; Mailman RB; Brundin P; Brundin L; Huang X
    Sci Rep; 2021 Dec; 11(1):24384. PubMed ID: 34934078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nigral iron deposition occurs across motor phenotypes of Parkinson's disease.
    Jin L; Wang J; Jin H; Fei G; Zhang Y; Chen W; Zhao L; Zhao N; Sun X; Zeng M; Zhong C
    Eur J Neurol; 2012 Jul; 19(7):969-76. PubMed ID: 22288465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of regional iron on the motor impairments of Parkinson's disease: A quantitative susceptibility mapping study.
    Guan X; Xuan M; Gu Q; Xu X; Huang P; Wang N; Shen Z; Xu J; Luo W; Zhang M
    J Magn Reson Imaging; 2017 May; 45(5):1335-1342. PubMed ID: 27545971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Motor associations of iron accumulation in deep grey matter nuclei in Parkinson's disease: a cross-sectional study of iron-related magnetic resonance imaging susceptibility.
    Martin-Bastida A; Lao-Kaim NP; Loane C; Politis M; Roussakis AA; Valle-Guzman N; Kefalopoulou Z; Paul-Visse G; Widner H; Xing Y; Schwarz ST; Auer DP; Foltynie T; Barker RA; Piccini P
    Eur J Neurol; 2017 Feb; 24(2):357-365. PubMed ID: 27982501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative evaluation of iron content in idiopathic rapid eye movement sleep behavior disorder.
    Sun J; Lai Z; Ma J; Gao L; Chen M; Chen J; Fang J; Fan Y; Bao Y; Zhang D; Chan P; Yang Q; Ye C; Wu T; Ma T
    Mov Disord; 2020 Mar; 35(3):478-485. PubMed ID: 31846123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct progression pattern of susceptibility MRI in the substantia nigra of Parkinson's patients.
    Du G; Lewis MM; Sica C; He L; Connor JR; Kong L; Mailman RB; Huang X
    Mov Disord; 2018 Sep; 33(9):1423-1431. PubMed ID: 29756399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of dopaminergic terminal dysfunction and microstructural abnormalities of the basal ganglia and the olfactory tract in Parkinson's disease.
    Scherfler C; Esterhammer R; Nocker M; Mahlknecht P; Stockner H; Warwitz B; Spielberger S; Pinter B; Donnemiller E; Decristoforo C; Virgolini I; Schocke M; Poewe W; Seppi K
    Brain; 2013 Oct; 136(Pt 10):3028-37. PubMed ID: 24014521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative susceptibility mapping of the midbrain in Parkinson's disease.
    Du G; Liu T; Lewis MM; Kong L; Wang Y; Connor J; Mailman RB; Huang X
    Mov Disord; 2016 Mar; 31(3):317-24. PubMed ID: 26362242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of Quantitative Susceptibility Mapping and Diffusion Kurtosis Imaging Provides Potential Biomarkers for Early-Stage Parkinson's Disease.
    Rong Y; Xu Z; Zhu Y; Zhang X; Lai L; Sun S; Gao M; Guo P; Zhang G; Geng Y; Ma X; Wu S; Yang L; Shen Z; Guan J
    ACS Chem Neurosci; 2022 Sep; 13(18):2699-2708. PubMed ID: 36047877
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.